BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, June 21, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
Breaking News: Trump administration impacts continue to roil the life sciences sector
Breaking News: Trump administration impacts continue to roil the life sciences sector
Breaking News: Trump administration impacts continue to roil the life sciences sector
Home
»
Topics
» BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric
RSS
Myotrophin expanded access program initiated
Aug. 16, 1996
Genetic insights into MS reported
Aug. 16, 1996
Pfizer investigates enantiomeric profiles of citalopram, fluoxetine
Aug. 16, 1996
Lamotrigine, valproate tested in mood disorders
Aug. 16, 1996
Meiji Seika claims bicyclic thiazoles for CNS disorders
Aug. 16, 1996
Allelix describes D4 antagonists for schizophrenia
Aug. 16, 1996
BTS-73947: new D1/D5 antagonist from Knoll
Aug. 16, 1996
Roche profiles pharmacokinetics, pharmacodynamics of new benzodiazepine
Aug. 16, 1996
first clinical study results reported for Ro-48-6791
Aug. 16, 1996
LY-23728, 5-HT2B antagonist reported by Lilly
Aug. 16, 1996
Previous
1
2
…
2714
2715
2716
2717
2718
2719
2720
2721
2722
…
2749
2750
Next